ijms-logo

Journal Browser

Journal Browser

Molecular and Cellular Mechanisms of Gynecologic Malignancies, Benign Diseases 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".

Deadline for manuscript submissions: closed (30 May 2024) | Viewed by 729

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan
2. School of Medicine, Tzu-Chi University, Hualien 970, Taiwan
Interests: gynecologic cancer; endometriosis; PCOS; target therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Women's health is a major topic of concern all over the world. During their lives, women may encounter the invasion of gynecologic malignancies, including ovarian cancer, cervical cancer, uterine corpus, and endometrial cancer, many of which may be unexpected and have huge consequences on patients and their families. Gynecologic malignancies per se and relevant complications significantly influence the life span and quality of affected women. Other benign gynecologic diseases, such as endometriosis and polycystic ovary syndrome (PCOS), can bring about negative effects in women's daily lives. Healthcare related to these conditions has been an important issue and remains to be explored. This Special Issue plans to provide an overview of the most recent advances in the underlying molecular and cellular mechanisms of gynecologic malignancies, benign diseases. It solicits any original contributions and reviews that explore the nature of gynecologic malignancies and benign diseases, associated therapies, and health impacts on women in different countries and communities. Studies discussing the health issues mentioned above are suitable for consideration in the Special Issue. Advances in or any cutting-edge research on affected women’s healthcare are especially welcomed to be published. The listed topics suggest just a few of the many possibilities. Potential topics include, but are not limited to, gynecologic malignancies, endometrial cancer, ovarian cancer, cervical cancer, uterine cancer, chemotherapy, target therapy, tumor markers, benign gynecologic diseases, endometriosis, and polycystic ovary syndrome.

You may find related papers collected in the Special Issue below:
https://www.mdpi.com/journal/ijms/special_issues/Gynecologic_Malignancies

Dr. Kuo-Hu Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecologic malignancies
  • endometrial cancer
  • ovarian cancer
  • cervical cancer
  • uterine cancer
  • chemotherapy
  • target therapy
  • tumor marker
  • benign gynecologic diseases
  • endometriosis
  • polycystic ovary syndrome

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2143 KiB  
Article
Preoperative Immune Cell Dysregulation Accompanies Ovarian Cancer Patients into the Postoperative Period
by Jonas Ulevicius, Aldona Jasukaitiene, Arenida Bartkeviciene, Zilvinas Dambrauskas, Antanas Gulbinas, Daiva Urboniene and Saulius Paskauskas
Int. J. Mol. Sci. 2024, 25(13), 7087; https://doi.org/10.3390/ijms25137087 - 28 Jun 2024
Viewed by 387
Abstract
Ovarian cancer (OC) poses a significant global health challenge with high mortality rates, emphasizing the need for improved treatment strategies. The immune system’s role in OC progression and treatment response is increasingly recognized, particularly regarding peripheral blood mononuclear cells (PBMCs) and cytokine production. [...] Read more.
Ovarian cancer (OC) poses a significant global health challenge with high mortality rates, emphasizing the need for improved treatment strategies. The immune system’s role in OC progression and treatment response is increasingly recognized, particularly regarding peripheral blood mononuclear cells (PBMCs) and cytokine production. This study aimed to investigate PBMC subpopulations (T and B lymphocytes, natural killer cells, monocytes) and cytokine production, specifically interleukin-1 beta (IL-1β), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12), and tumor necrosis factor alpha (TNFα), in monocytes of OC patients both preoperatively and during the early postoperative period. Thirteen OC patients and 23 controls were enrolled. Preoperatively, OC patients exhibited changes in PBMC subpopulations, including decreased cytotoxic T cells, increased M2 monocytes, and the disbalance of monocyte cytokine production. These alterations persisted after surgery with subtle additional changes observed in PBMC subpopulations and cytokine expression in monocytes. Considering the pivotal role of these altered cells and cytokines in OC progression, our findings suggest that OC patients experience an enhanced pro-tumorigenic environment, which persists into the early postoperative period. These findings highlight the impact of surgery on the complex interaction between the immune system and OC progression. Further investigation is needed to clarify the underlying mechanisms during this early postoperative period, which may hold potential for interventions aimed at improving OC management. Full article
Show Figures

Figure 1

Back to TopTop